Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study

BACKGROUND: Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O(6) methylguanine DNA methyltransferase (MGMT) that renders the tumors resistant to temozolomide...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Mohummad A., Brekke, Jorunn, Arnesen, Victoria, Hannisdal, Marianne H., Navarro, Andrea G., Waha, Andreas, Herfindal, Lars, Rygh, Cecilie B., Bratland, Eirik, Brandal, Petter, Haasz, Judit, Oltedal, Leif, Miletic, Hrvoje, Lundervold, Arvid, Lie, Stein A., Goplen, Dorota, Chekenya, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416034/
https://www.ncbi.nlm.nih.gov/pubmed/32578964
http://dx.doi.org/10.1002/iid3.315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416034/
https://www.ncbi.nlm.nih.gov/pubmed/32578964
http://dx.doi.org/10.1002/iid3.315

Ejemplares similares